DOCSLIB.ORG

January 28, 2021 VIA EMAIL and FEDEX Dr. Rochelle P. Walensky

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
January 28, 2021 VIA EMAIL and FEDEX Dr. Rochelle P. Walensky January 28, 2021 VIA EMAIL AND FEDEX Dr. Rochelle P. Walensky Director, Centers for Disease Control and Prevention 1600 Clifton Road Atlanta, GA 30329 [email protected] Dear Dr. Walensky: We write on behalf of Informed Consent Action Network to bring to your attention a letter previously sent to Secretary Azar on December 29, 2020 (enclosed) and Dr. Redfield’s response dated January 19, 2021 (enclosed). ICAN has requested that federal health authorities require health providers to report all COVID-19 vaccine adverse reactions, apart from mild ones, to the CDC’s Vaccine Adverse Events Reporting System (“VAERS”). While Dr. Redfield’s letter is appreciated, it did not respond to whether this request will be implemented. Can you please advise whether this requirement will be put in place? Without this rule, as detailed in our opening letter, only certain narrow categories of adverse reactions are required to be reported. For example, “serious” adverse reactions is a very limited category of events. This limitation would exclude many chronic diseases and reactions that the public would find concerning. The CDC’s V-Safe program provides a further hurdle since it directs adverse reaction reports to be submitted through this application and not to VAERS. These reports are therefore less likely to end up on VAERS further reducing the utility of the already handicapped VAERS system, as detailed in our letter of December 29, 2020. Further, Dr. Redfield did not address ICAN’s concern with regard to long-term safety tracking of all adverse events following COVID-19 vaccines. As you are aware, these are novel vaccine platforms. Pfizer’s and Moderna’s clinical trial protocols are deficient in tracking serious adverse events for an adequate period of time. The need for longer-term multi-year safety surveillance cannot be overstated. Compounding this concern is the fact that both manufacturers have already begun the unblinding process and are vaccinating their placebo groups. Placebo comparator groups will no longer exist beyond 6 months post-second dose. At ICAN’s request, we include with this follow-up letter a copy of a letter exchange ICAN had with HHS regarding vaccine safety. We note that the response from HHS was approved by the CDC. It includes an exchange with regard to VAERS and vaccine safety, in general, that ICAN sincerely hopes you, as the new CDC Director, will take the opportunity to review. As with most things, there is room for improvement and ICAN merely asks that you review these letters and consider whether there is any room for improvement in the area of vaccine safety. The children injured by vaccines are as worthy of your attention as those that could suffer from an infectious disease. Kind Regards, Aaron Siri, Esq. Elizabeth A. Brehm, Esq. Enc: December 29, 2020 ICAN letter to Secretary Azar; January 19, 2021 Dr. Redfield response letter; ICAN and HHS letter exchange December 29, 2020 VIA EMAIL AND FEDEX Mr. Alex Azar Secretary, HHS U.S. Department of Health & Human Services 200 Independence Avenue, S.W. Washington, D.C. 20201 [email protected] Re: Mandated Reportable Events for COVID-19 Vaccines Authorized or Licensed in the United States Pursuant to 42 U.S.C. § 300aa-25 Dear Secretary Azar: We write on behalf of our client, Informed Consent Action Network (“ICAN”), to make an important request regarding safety surveillance of any COVID-19 vaccine which is, or will be, authorized or licensed for use in the United States. Pursuant to 42 U.S.C. § 300aa-25, as Secretary of Health and Human Services, you have the authority to require health care providers and vaccine manufacturers to report adverse reactions, events, and contraindications following the receipt of a vaccine to the Vaccine Adverse Events Reporting System (“VAERS”) – a system co-administered by the Centers for Disease Control & Prevention (“CDC”) and the Food and Drug Administration (“FDA”).1 ICAN therefore requests that you immediately make it mandatory that all adverse events following a COVID-19 vaccination, with the exception of mild events, be reported by vaccine manufacturers and all health care providers to VAERS. Currently, only a very limited number of adverse events must be reported pursuant to 42 U.S.C. § 300aa-25, namely shoulder injuries or fainting within seven days of receiving the vaccine or any serious issue resulting from such shoulder injury or fainting.2 The Pfizer emergency use authorization does require that health care providers report a limited list of serious adverse events, however this list is not exhaustive and would not capture all adverse events including, for example, 1 See 42 U.S.C. § 300aa-25(b). 2 See 42 U.S.C. § 300aa-25(b) and https://vaers.hhs.gov/docs/VAERS_Table_of_Reportable_Events_Following_ Vaccination.pdf. Bell’s Palsy, nor is there any indication the requirement to report such events will apply once licensure is granted for this vaccine.3 Both the CDC and the FDA have acknowledged the need for comprehensive safety surveillance as the nation implements the widespread administration of COVID-19 vaccinations. Tom Shimabukuro (Captain, U.S. Public Health Service Vaccine Safety, Team Lead of COVID- 19 Response for the Centers for Disease Control and Prevention) recently presented at the Clinician Outreach and Communication Activity Webinar, held on December 14, 2020, about the importance of safety surveillance: “Clinical trials used to authorize or license vaccines for use - may not detect all types of adverse events, especially ones that are rare or take longer to occur (delayed onset) and - don’t always look at special populations (e.g., pregnant women and people with certain pre-existing medical conditions).”4 The FDA has also acknowledged that “[f]ollowing authorization of the vaccine, use in large numbers of individuals may reveal additional, potentially less frequent and/or more serious adverse events not detected in the trial safety population of approximately 30,000 participants over the period of follow-up at this time.”5 The FDA has stated, then, that “[a]ctive and passive safety surveillance will continue during the post-authorization period to detect new safety signals.”6 Safety surveillance must therefore be undertaken as thoroughly as possible. The need for long-term safety tracking of all adverse events (other than mild local or systemic reactions) is also critical. The Moderna vaccine trial protocol calls for monitoring of certain adverse events through the duration of the study (759 days) and the Pfizer vaccine trial protocol calls for monitoring for only 6 months post-second dose. Neither of these is an appropriate time-period to capture potential serious long-term adverse events including cancer or any neurological, cardiovascular, or autoimmune diseases. Additionally, the unblinding and/or cross-over (either blinded or open label) which both Pfizer and Moderna are currently planning obviate the comparator placebo group, creating yet another concern. Compounding this problem is the well and long-known fact that VAERS suffers from significant inadequacies. This passive system collects a drastically low percentage of actual adverse events that occur, with one study funded by the Federal government finding that only 1% of vaccine adverse events are reported to VAERS.7 Many health care professionals do not report to VAERS because they are not mandated to do so, they do not know what adverse events to look for or to connect to a vaccination, or because there is no routine follow-up with doctor or patient after an adverse event is reported. Until these very serious issues are corrected, reporting of any and all adverse events (with the exception of mild local and systemic reactions) must be required in an attempt to identify any signals or causal relationships missed in the limited clinical trials for COVID-19 vaccines. 3 https://www.fda.gov/media/144413/download. 4 https://emergency.cdc.gov/coca/calls/2020/callinfo_121420.asp. 5 https://www.fda.gov/media/144434/download at 50. 6 Id. 7 https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf. Page 2 of 3 In the absence of any liability on the part of the manufacturers and vaccine administrators, the American public must be confident that safety surveillance is the highest priority with these vaccines. For this and the other reasons above, detailed and thorough mandates regarding adverse event reporting must be put into place. Requiring that health care providers and vaccine manufacturers report all adverse events, other than mild reactions, following receipt of a COVID-19 vaccine is critical to assuring that any safety issues with these products are captured and addressed. This minimal level of safety surveillance of these innovative and novel vaccines is critical to increase confidence with the American public that decisions pertaining to any coronavirus vaccine are made with a sound, independent scientific basis, with people’s safety at the forefront. We ask that you respond to ICAN’s request and address the serious issue identified above forthwith in order to avoid erosion of confidence in the HHS, Operation Warp Speed, and vaccine programs generally. Very truly yours, Aaron Siri, Esq. Elizabeth Brehm, Esq. Page 3 of 3 January 19, 2021 Ms. Elizabeth Brehm, Esq. Siri & Glimstad 200 Park Avenue 17th Floor New York, New York 10166 Dear Ms. Brehm: Thank you for your letter to Secretary of Health and Human Services Alex M. Azar II requesting that all adverse events following a Coronavirus Disease 2019 (COVID-19) vaccine, with the exception of mild events, be reported by vaccine manufacturers and all health care providers to the Vaccine Adverse Events Reporting System (VAERS). I am responding on behalf of Secretary Azar. use, is an important part of a successful national vaccination effort.
Load more

Recommended publications
  • COVID Update May 21, 2021
    COVID Update May 21, 2021 The US Centers for Disease Control and Prevention announced on Thursday May 13 that fully vaccinated people can go without masks in most circumstances. The new guidance was based on analysis of a new study that found that real-life use of the Moderna and Pfizer vaccines provided 94% protection for over 4,000 front-line health care workers immunized at the beginning of the vaccine rollout who had weekly COVID testing following vaccination. A single dose provided 82% protection, the CDC-led team reported in the agency's weekly report, the MMWR. The new study also showed that fully vaccinated people are unlikely to develop asymptomatic infection and unknowingly shed virus, because even if infected, they have a very low viral load. This corroborates the findings of three major studies that have shown that fully vaccinated people are not likely to test positive for coronavirus, which indicates they are not carrying it in their bodies, whether they have symptoms or not. A similar study from Israel also found vaccinated people who got infected had a lower viral load -- fourfold lower than unvaccinated people. The new CDC guidance states that vaccinated individuals can in general safely remove their masks in large and small groups, indoors and out. However, it was recommended that masks continue to be worn on public transportation (including trains, buses, airplanes), and in homeless shelters and correctional facilities. The new guidance does not apply to health care settings. Concern was immediately raised regarding increased risk to the unvaccinated, including children under 12 and individuals who are immunocompromised in whom the vaccine may not be effective; the fact that the new guidance relies on unvaccinated individuals continuing to mask and distance, which may not occur; and the known presence in the U.S.
    [Show full text]
  • Hiv Prevention Drug: Billions in Corporate Profits After Millions in Taxpayer Investments
    HIV PREVENTION DRUG: BILLIONS IN CORPORATE PROFITS AFTER MILLIONS IN TAXPAYER INVESTMENTS HEARING BEFORE THE COMMITTEE ON OVERSIGHT AND REFORM HOUSE OF REPRESENTATIVES ONE HUNDRED SIXTEENTH CONGRESS FIRST SESSION MAY 16, 2019 Serial No. 116–24 Printed for the use of the Committee on Oversight and Reform ( Available on: http://www.govinfo.gov http://www.oversight.house.gov http://www.docs.house.gov U.S. GOVERNMENT PUBLISHING OFFICE 36–660 PDF WASHINGTON : 2019 COMMITTEE ON OVERSIGHT AND REFORM ELIJAH E. CUMMINGS, Maryland, Chairman CAROLYN B. MALONEY, New York JIM JORDAN, Ohio, Ranking Minority Member ELEANOR HOLMES NORTON, District of JUSTIN AMASH, Michigan Columbia PAUL A. GOSAR, Arizona WM. LACY CLAY, Missouri VIRGINIA FOXX, North Carolina STEPHEN F. LYNCH, Massachusetts THOMAS MASSIE, Kentucky JIM COOPER, Tennessee MARK MEADOWS, North Carolina GERALD E. CONNOLLY, Virginia JODY B. HICE, Georgia RAJA KRISHNAMOORTHI, Illinois GLENN GROTHMAN, Wisconsin JAMIE RASKIN, Maryland JAMES COMER, Kentucky HARLEY ROUDA, California MICHAEL CLOUD, Texas KATIE HILL, California BOB GIBBS, Ohio DEBBIE WASSERMAN SCHULTZ, Florida RALPH NORMAN, South Carolina JOHN P. SARBANES, Maryland CLAY HIGGINS, Louisiana PETER WELCH, Vermont CHIP ROY, Texas JACKIE SPEIER, California CAROL D. MILLER, West Virginia ROBIN L. KELLY, Illinois MARK E. GREEN, Tennessee MARK DESAULNIER, California KELLY ARMSTRONG, North Dakota BRENDA L. LAWRENCE, Michigan W. GREGORY STEUBE, Florida STACEY E. PLASKETT, Virgin Islands RO KHANNA, California JIMMY GOMEZ, California ALEXANDRIA OCASIO-CORTEZ, New York AYANNA PRESSLEY, Massachusetts RASHIDA TLAIB, Michigan DAVID RAPALLO, Staff Director ALI GOLDEN, Chief Health Counsel ELISA LANIER, Director of Operations and Chief Clerk CHRISTOPHER HIXON, Minority Chief of Staff CONTACT NUMBER: 202-225-5051 (II) CONTENTS Page Hearing held on May 16, 2019 ..............................................................................
    [Show full text]
  • IAS 2009: Conference Report
    July-August 2009 WWW.IAVIREPORT.ORG | VOLUME 13, NUMBER 4 IAS 2009: Conference Report Challenge Models Characterizing and optimizing viral challenge models for vaccine research EDITOR’S LETTER What if there were magic pills that could effectively treat HIV infection, prevent HIV-infected indi- viduals from transmitting the virus to others, reduce prevalence of tuberculosis, and perhaps even protect uninfected individuals from acquiring HIV? Oh wait, maybe there are. They’re called antiretrovirals (ARVs), and they have revolutionized the treatment of HIV infection. So far, the road to developing biomedical interventions to prevent HIV infection has been a bit rockier. In his talk at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Pre- vention, held recently in Cape Town, South Africa (see Everything from Cause to Cure for our report on the conference), Ronald Gray of Johns Hopkins University noted that of 29 trials evaluating the efficacy of different biomedical HIV prevention strategies, only four have shown significant success, and five have wshown possible harm. Until an effective vaccine or other HIV prevention strategy is developed, ARVs are being billed as one of the greatest hopes for controlling the global spread of HIV. One ARV-based approach to prevention is getting more HIV infected individuals on therapy. Evidence is accumulating that starting ARV treatment earlier in the course of HIV infection is beneficial. For prevention, the idea is that therapy, which efficiently and rapidly reduces viral load, could prevent those people already infected from transmitting HIV to others. This serves as the basis for the so-called test and treat strategy, which is explored in this issue (see Test and Treat on Trial) .
    [Show full text]
  • Fund to Retain Clinical Scientists to Bolster the Long-Term Careers of Young Physician Scientists
    Kristin Roth-Schrefer, Communications Director [email protected] / 212.974.7003 Nina Chung, Communications Assistant [email protected] / 212.974.7006 Leslie Engel, Program Associate for Medical Research [email protected] / 212.974.7106 Ten Institutions Receive Grants Totaling $5.4 Million Through Inaugural Fund to Retain Clinical Scientists To Bolster the Long-term Careers of Young Physician Scientists NEW YORK, NY, December 3, 2015 – The Doris Duke Charitable Foundation today announced grants totaling $5.4 million to 10 medical schools to establish a Fund to Retain Clinical Scientists within each of their institutions. Each school will receive $540,000 over five years to provide stronger institutional support and supplemental funds for early-career physician scientists to maintain productivity during periods of excessive extraprofessional demands. DDCF launched the Fund to Retain Clinical Scientists (the Fund) to build upon a growing momentum in the medical research field toward supporting young physician scientists through phases of intense, extraprofessional career obstacles. Studies have revealed that up to 44 percent of young physicians with full-time faculty appointments at academic medical schools leave their posts within 10 years.1 Furthermore, while women enter academic medical centers at about the same rate as men, they make up only 19 percent of faculty at the full professor level.2 The causes of this disparity are varied and complex, but one contributing factor is the load of transitory but significant outside responsibilities such as childcare, elder care or family illness that may arise and preclude the career growth of many young faculty members, particularly women. “As a foundation committed to fostering the careers of physician scientists in academic medicine, we sought a way to retain promising early-career faculty during times they are most challenged by caregiving demands,” said Betsy Myers, program director for Medical Research.
    [Show full text]
  • Ohio Stands Up! and Kristen Beckman, ) Plaintiffs, ) ) Attorneys: ) Thomas Renz (Bar ID 98645) ) 1907 W State St
    IN THE UNITED STATES DISTRICT COURT WESTERN DIVISION FOR THE NORTHERN DISTRICT OF OHIO Ohio Stands Up! and Kristen Beckman, ) Plaintiffs, ) ) Attorneys: ) Thomas Renz (Bar ID 98645) ) 1907 W State St. #162 ) Fremont, OH 43420 ) ) CASE NO.: 3:20-cv-02814-JRK & ) ) Robert Gargasz (Bar ID 7136) ) 1670 Cooper Foster Park Rd. ) Lorain, OH 44053 ) ) & ) ) N. Ana Garner (NM Bar ID#921) ) 1000 Cordova Pl., #644 ) Santa Fe, NM 87505 ) (pending pro hac vice approval) ) ) -vs- ) JUDGE: James R. Knepp II ) The United States Department of Health & ) Human Services, Center for Disease Control ) (CDC), Secretary Norris Cochran, Director ) Rochelle Walensky, The National Center for ) Health Statistics (NCHS), Director Brian C. ) AMENDED COMPLAINT Moyer, and John and/or Jane Doe[s] 1-20, ) ) Defendants. ) Page 1 of 73 Table of Contents COMPLAINT: FEDERAL QUESTION ........................................................................................ 5 I. Introduction ............................................................................................................................. 5 II. Prayers for Relief .................................................................................................................... 7 III. Parties ................................................................................................................................... 8 A. Plaintiffs and Injury .......................................................................................................... 8 B. Defendants .....................................................................................................................
    [Show full text]
  • As Physicians and Scientists Who Have Seen Firsthand the Value of U.S
    January 31, 2017 The President The White House 1600 Pennsylvania Ave, NW Washington, DC, 20500 Dear Mr. President: As physicians and scientists who have seen firsthand the value of U.S. leadership in global health, we are writing to share our insights on the impacts of the investments this country has made and the vital importance of continuing them. The global health threats recently posed by influenza, Ebola and Zika make the increasing frequency and severity of transnational infectious disease outbreaks impossible to ignore. This pattern will continue. Addressing infectious diseases abroad is essential to protecting the American people at home and our economic interests abroad. The United States has been a longstanding leader in global health. Our country has been extraordinarily effective in improving the health of millions while advancing our global health security and strengthening our standing with international leaders and trade partners. We urge you to build on that leadership. The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the most important and ambitious global health program ever implemented by any nation to address a single disease has had measurable impact on the lives of millions. PEPFAR supports lifesaving antiretroviral treatment for nearly 11.5 million people, has prevented two million babies from being born with HIV, and trained hundreds of thousands of health care workers in low-income countries. These remarkable achievements were made possible by the leadership and support of Administrations from both parties, by strong bipartisan Congressional support, and by scientific advances in HIV prevention and treatment developed through research supported by the National Institutes of Health.
    [Show full text]
  • Better Healthcare Newsletter from Patrick Malone As the New
    Subscribe Past Issues Translate RSS Hi, just a reminder that you're receiving this email because you have expressed an interest in Patrick Malone & Associates. Don't forget to add [email protected] to your address book so we'll be sure to land in your inbox! You may unsubscribe if you no longer wish to receive our emails. Call Us Today 202-742-1500 Better Healthcare Newsletter from Patrick Malone IN THIS ISSUE As the new administration settles in, differences will be stark on health care Why's this doc smiling? Science is back ... Biden will reverse predecessor's policies and set new priorities in health care Improving U.S. health: an expansive view Data will be in high Health care has dominated national politics for more than a decade. demand Voters told pollsters it was a top concern heading into the 2020 campaign, and that only intensified with the coronavirus pandemic. As What's the future for the new administration launches, this is a good time to look at departing officials? the health care agenda and how it differs from the last administration. The constant tumult of the recent years provides a warning, though, BY THE that political prognosticating can be uncertain, at best. NUMBERS Still, broad outlines have emerged already about stark differences that should define the 46th versus the 45th presidency. These will have 2.3 million direct effects on your finances, health, and well-being, so let’s jump into Increased number of a longer view of Bidenhealth and what it may mean to the country.
    [Show full text]
  • Webinar Transcript
    1 AMERICAN PUBLIC HEALTH ASSOCIATION and THE NATIONAL ACADEMY OF MEDICINE + + + + + RESPONDING TO COVID-19: A SCIENCE-BASED APPROACH + + + + + WEBINAR #12: MANAGING ONGOING SURGES -LESSONS FROM THE FRONT LINES + + + + + WEDNESDAY JULY 29, 2020 + + + + + The webinar convened at 5:00 p.m. Eastern Daylight Time, Rochelle Walensky, Moderator, presiding. PRESENT ROCHELLE WALENSKY, MD, MPH, Harvard Medical School and Massachusetts General Hospital, Moderator JONATHAN LEWIN, MD, Emory University and Emory Healthcare GREG ADAMS, Kaiser Foundation Health Plan, Inc. and Hospitals HOWARD ZUCKER, MD, JD, New York State Health Commissioner ALSO PRESENT GEORGES C. BENJAMIN, Executive Director, American Public Health Administration 2 C O N T E N T S Welcome - Dr. Georges Benjamin ................ 3 Dr. Rochelle Walensky ......................... 5 Introduction of Panelists .................... 23 Dr. Jonathan Lewin ........................... 23 Mr. Greg Adams ............................... 37 Dr. Howard Zucker ............................ 50 Questions .................................... 67 3 P-R-O-C-E-E-D-I-N-G-S 5:00 p.m. DR. BENJAMIN: Good evening. I'm Dr. Georges Benjamin. And welcome to the 12th webinar in the COVID-19 Conversations Series brought to you by the American Public Health Association and the National Academy of Medicine. Today's webinar is entitled Managing Ongoing Surges: Lessons from the Front Lines. Today's webinar has been approved for one and half hours continuing education credits for CHES, CME, CNE, and CPH. None of the speakers has any relevant financial relationship to disclose. Please note, that if you want continuing education credit, you should have registered with your first and last name. Now, everyone who wants credit, must have their own registration, and watch today's event in its entirety.
    [Show full text]
  • North American COVID-19 Policy Response Monitor: United States
    North American COVID-19 Policy Response Monitor: United States December 23, 2020 What is the North American COVID-19 Policy Response Monitor? The North American COVID-19 policy monitor has been designed to collect and organize up-to-date information on how jurisdictions are responding to the crisis. It summarizes responses of health systems as well as wider public health initiatives. The North American policy monitor is an offshoot of the international COVID-19 Health System Response Monitor (HSRM), a joint undertaking of the WHO Regional Office for Europe, the European Commission and the European Observatory on Health Systems and Policies. Contents List of Acronyms and Abbreviations ............................................................................................................. 2 1. Preventing Transmission ........................................................................................................................... 3 2. Ensuring sufficient physical infrastructure and workforce capacity ....................................................... 12 3. Providing health services effectively....................................................................................................... 17 4. Paying for services .................................................................................................................................. 20 5. Governance ............................................................................................................................................. 23 6. Measures
    [Show full text]
  • June 10, 2021 Delivered Via E-Mail Dr. Rochelle Walensky Director
    June 10, 2021 Delivered via E-Mail Dr. Rochelle Walensky Director Centers for Disease Control and Prevention 1600 Clifton Road Atlanta, GA 30329 Dear Dr. Walensky: We write today out of concern that you may have given incomplete or inaccurate testimony during the May 11, 2021, U.S. Senate Committee on Health, Education, Labor, and Pensions (Committee) hearing regarding the clearance process for the Centers for Disease Control and Prevention’s (CDC) Operational Strategy for K-12 Schools (“School Re-Opening Guidance” or “Guidance”).1 Specifically, your testimony appears to be inconsistent with representations in your April 22, 2021, letter to Ranking Member Burr and with email correspondence between the CDC, Biden Administration political appointees, and teachers’ unions that was recently made public. The Committee’s May 11th hearing was the first opportunity for Senators to question you about the school re-opening guidance since the extent of the CDC’s cooperation with the teachers’ unions was made public. You testified that edits from the teachers’ unions were limited to addressing “what happens if you have immunocompromised teachers.” You further testified that the level of collaboration between the teachers’ unions and the CDC was routine, “[a]s a matter of practice, the CDC engages with stakeholders, with consumers who take our guidance, who use our guidance before it is finalized so we can understand whether it addresses their needs. For our school guidance, we did that with 50 different stakeholders, over 50, actually.” Compared to the emails between the CDC and the teachers’ unions, your testimony seems – at a minimum incomplete – if not inaccurate.
    [Show full text]
  • BSC, NCIPC Minutes
    NCIPC Board of Scientific Counselors Open to the Public February 16, 2021 National Center for Injury Prevention and Control Centers for Disease Control and Prevention Atlanta, Georgia Table of Contents Summary Proceedings ............................................................................................................... 3 Call to Order / Roll Call / Introductions / Meeting Logistics ......................................................... 3 Approval of Minutes ................................................................................................................... 4 NCIPC Director’s Update ........................................................................................................... 4 Discussion Points ................................................................................................................... 8 Suicide Prevention Strategic Plan and Priorities and Goals.......................................................10 CDC’s Comprehensive Public Health Approach to Suicide Prevention ..................................10 Suicide Research Priorities Update .......................................................................................14 Discussion Points ..................................................................................................................16 Workgroup Updates ..................................................................................................................20 NCIPC Diversity, Equity, and Inclusion (DEI) Workgroup.......................................................20
    [Show full text]
  • Dear President Obama
    January 20, 2016 President Barack Obama The White House 1600 Pennsylvania Ave NW Washington, DC 20500 Dear President Obama: As your Administration completes work on finalizing the FY2016 operating budget for the National Institutes of Health, we write to ask that the final FY2016 NIH budget include the $100 million increase for HIV/AIDS research for FY2016 above the FY2015 level that your Administration publically committed to in your FY2016 budget proposal released in February, 2015. This is a time to prioritize, not cut or flat fund HIV/AIDS research. NIH-funded HIV/AIDS research has supported innovative basic science for better drug therapies, behavioral and biomedical prevention interventions that have saved and improved the lives of millions. These advances hold great promise for significantly reducing HIV infection rates and providing more effective treatments for those living with HIV/AIDS in the coming decade. Research advances to develop a preventive vaccine and a cure for HIV infection hold the potential to “end the scourge of HIV/AIDS” as you so eloquently stated in your State of the Union address. Thank you for considering these views.* Respectfully Yours, Alabma Amanda Wlig, PhD, RD, University of Alabama at Birmingham James Raper, PhD, JD, University of Alabama at Birmingham Michael Saag, MD, University of Alabama at Birmingham Olaf Kutsch, Professor, University of Alabama at Birmingham Safiya George, PhD Suzanne Prevost, RN, PhD, University of Alabama California Andrew Henkin, BSW, Harm Reduction Services Andrew Scheer, BS, MSW; LCSW Argentina Servin, MD,MPH, University of California, San Diego Brooke West, PhD Celsa Spina, PhD., University of California, San Diego Christopher Mathews, M.D., University of California, San Diego 2 Colleen Hoff, PhD, San Francisco Cory White, B.S.
    [Show full text]